<\/p>\n
Clinicians report growing numbers of cannabis\u2011induced psychotic episodes concentrated among daily users of high\u2011THC products, prompting calls for health\u2011led interventions, better addiction services and limits on the most harmful strains even as national use declines.<\/p>\n<\/div>\n
Cannabis-induced psychosis is emerging as a growing clinical concern in the UK, even as overall use of the drug falls. Speaking to the Daily Mail, Dr Niall Campbell, a consultant psychiatrist at the Priory rehabilitation centre, warned that he has seen \u201ca visible rise in the number of people needing intensive support for psychosis as a result of cannabis use\u201d, and blamed easy online access to high\u2011potency \u201cskunk\u201d varieties. According to that report, what can begin as transient paranoia after smoking a few joints can escalate, and in some cases lead to persistent psychotic states with severe consequences for mood and suicide risk. <\/p>\n
Official prevalence figures, however, show a more complex picture. The Office for National Statistics estimates that about 2.3 million people aged 16 to 59 reported using cannabis in the year to March 2024 \u2014 roughly 6.8% of that age group \u2014 and that overall frequent use has fallen compared with a decade earlier. The contrast between falling overall use and rising treatment demand for cannabis\u2011related psychosis is at the heart of current concern. <\/p>\n
Medical research helps to explain why a smaller number of users could be responsible for a disproportionate share of harm. A multicentre case\u2013control study across European cities found that daily use, and in particular daily use of high\u2011potency cannabis, is strongly associated with first\u2011episode psychosis \u2014 in some analyses approaching a five\u2011fold increased risk. Researchers at King\u2019s College London have also reported that frequent use raises the likelihood of clinical psychosis independently of inherited genetic risk, and they have emphasised the particular danger posed by products with high THC content. <\/p>\n
Clinically, substance\u2011related psychosis presents in the familiar ways: hallucinations, delusional thinking and dissociation, and can be triggered or worsened by intoxication and by withdrawal. NHS guidance notes that while substance\u2011induced psychosis will remit for many people, it can persist in others and requires careful medical assessment. The pattern seen in cohort studies is troubling: patients with first\u2011episode psychosis who continue to use cannabis tend to have more severe symptoms, poorer social functioning and worse outcomes at follow\u2011up than those who stop. <\/p>\n
Those longer\u2011term follow\u2011up studies also underline an important treatment message: continued cannabis use after a psychotic episode predicts a poorer course of illness. The EDEN study of first\u2011episode patients found that ongoing consumption was associated with worse symptomatic and functional outcomes at six and 12 months, reinforcing the need to integrate addiction treatment with early psychosis services. Public\u2011health researchers have argued that reducing the availability of high\u2011potency products could materially lower rates of first\u2011episode psychosis in settings where such products are common. <\/p>\n
Policy debate is beginning to catch up with the clinical evidence. The London Drugs Commission this year recommended a shift away from criminal penalties for natural cannabis and called for an expanded public\u2011health response that reduces reliance on stop-and\u2011search, improves education and strengthens treatment services for those harmed by cannabis. The London mayor has signalled support for some of those recommendations, reflecting an appetite \u2014 at least in the capital \u2014 for a different balance between criminal enforcement and health\u2011led interventions. <\/p>\n
Taken together, the clinical warnings, epidemiology and research suggest a targeted public\u2011health problem rather than a simple surge in recreational use: stronger products and persistent use appear to be concentrating harms among a subset of users. Clinicians and campaigners say the response should combine improved access to addiction and mental\u2011health services, clearer public messaging about the risks of daily and high\u2011THC use, and policy measures to limit the most harmful products \u2014 while recognising that for many occasional users the risk profile is lower. As Dr Campbell told the Daily Mail, what begins with a few joints can escalate, and for a minority the consequences can be long lasting \u2014 a reminder that policy and services must keep pace with changes in the market for the drug. <\/p>\n